A meta-analysis of placebo-controlled clinical trials assessing the efficacy and safety of incretin-based medications in patients with type 2 diabetes.
about
Safety of dipeptidyl peptidase 4 inhibitors: a perspective reviewSaxagliptin overview: special focus on safety and adverse effectsAntiobesity pharmacotherapy: new drugs and emerging targetsNew advances in models and strategies for developing anti-obesity drugs.Safety and Tolerability of Glucagon-Like Peptide-1 Receptor Agonists Utilizing Data from the Exenatide Clinical Trial Development Program.Comparative effectiveness of dipeptidylpeptidase-4 inhibitors in type 2 diabetes: a systematic review and mixed treatment comparisonObesity pharmacotherapy: what is next?Comparison of GLP-1 analogues versus sitagliptin in the management of type 2 diabetes: systematic review and meta-analysis of head-to-head studies.Adherence to Insulin Pen Therapy Is Associated with Reduction in Healthcare Costs Among Patients with Type 2 Diabetes MellitusThe role of incretin therapy at different stages of diabetes.Effects of diet soda on gut hormones in youths with diabetes.Efficacy and safety of vildagliptin, sitagliptin, and linagliptin as add-on therapy in Chinese patients with T2DM inadequately controlled with dual combination of insulin and traditional oral hypoglycemic agentComparison of vildagliptin twice daily vs. sitagliptin once daily using continuous glucose monitoring (CGM): crossover pilot study (J-VICTORIA study).Effects of exenatide and liraglutide on heart rate, blood pressure and body weight: systematic review and meta-analysis.The role of co-morbidity in the selection of antidiabetic pharmacotherapy in type-2 diabetes.Randomized trial of continuous subcutaneous delivery of exenatide by ITCA 650 versus twice-daily exenatide injections in metformin-treated type 2 diabetesDipeptidyl Peptidase-4 Inhibitors and the Risk of Acute Pancreatitis in Patients With Type 2 Diabetes in Taiwan: A Population-Based Cohort Study.Incretin-Based Therapy and Risk of Pancreatic Cancer in Patients with Type 2 Diabetes Mellitus: A Meta-analysis of Randomized Controlled Trials.Real-world cost-effectiveness: lower cost of treating patients to glycemic goal with liraglutide versus exenatide.Exenatide Add-on to Continuous Subcutaneous Insulin Infusion Therapy Reduces Bolus Insulin Doses in Patients with Type 2 Diabetes: A Randomized, Controlled, Open-Label Trial.Sitagliptin or exenatide once weekly for type 2 diabetes: comparison of the clinical trials.From theory to clinical practice in the use of GLP-1 receptor agonists and DPP-4 inhibitors therapy.Dipeptidyl peptidase-4 inhibitors and preservation of pancreatic islet-cell function: a critical appraisal of the evidence.Linagliptin for the treatment of type 2 diabetes (pharmacokinetic evaluation).Liraglutide: a review of its use in the management of type 2 diabetes mellitus.A review of gliptins in 2011.The efficacy and safety of vildagliptin in patients with type 2 diabetes: a meta-analysis of randomized clinical trials.GLP-1 based therapies: differential effects on fasting and postprandial glucose.Longer term safety of dipeptidyl peptidase-4 inhibitors in patients with type 2 diabetes mellitus: systematic review and meta-analysis.Comparative clinical pharmacokinetics of dipeptidyl peptidase-4 inhibitors.Individualized treatment of type 2 diabetes mellitus using noninsulin agents: clinical considerations for the primary care physician.Clinical pearls for initiating and utilizing liraglutide in patients with type 2 diabetes.Extra-pancreatic effects of incretin-based therapies: potential benefit for cardiovascular-risk management in type 2 diabetes.Cardiovascular effects of gliptins.Treating the obese diabetic.Cardiovascular effects of dipeptidyl peptidase-4 inhibitors: from risk factors to clinical outcomes.Exenatide twice daily: a review of its use in the management of patients with type 2 diabetes mellitus.HTA agencies facing model biases: the case of type 2 diabetes.Cardiovascular effects of anti-diabetes drugs.A review of glycemic efficacy of liraglutide once daily in achieving glycated hemoglobin targets compared with exenatide twice daily, or sitagliptin once daily in the treatment of type 2 diabetes.
P2860
Q26863262-1C5C58DB-71EF-493D-8B7E-724C3DD3D95CQ28278863-412E788E-8CF2-4536-86B2-FCBA4E7D9DCFQ30354242-C77132C9-5485-414B-BA28-C84C703716A4Q30429816-262BDB8D-4D42-42D3-985A-4F171A884ED9Q31066859-DB8725BC-0761-4974-BB6C-6FC2202AAC2EQ33785197-3EFD857D-4009-455E-B2A9-00B97A66D32CQ33827988-98656507-2BF8-4768-AF88-E3D56E9DCF99Q33999894-5DE74764-5A2B-47FB-BC5D-241AC1DEFAF5Q35741281-49062B95-9155-4998-924C-559D91362957Q35760288-403AAD4F-79A0-439B-B9F3-46B17A7611A2Q35898300-0D8E11C0-1256-403D-B6C4-184BBBE17A5BQ36192977-E5602A3D-A055-4630-80B7-B70CA78514C4Q36316467-69CC2987-19DE-4D9D-B657-DCDB16E1D97DQ36584204-53F277C4-1607-4F49-B5E3-5AFF4DFCC018Q36877514-56D3C415-4FBB-45B6-9E63-7E897F2A2C12Q37106564-3446D1DF-8FBC-43FB-BF5B-7E9FDC3E59F5Q37176363-2AB61EE5-DB7B-4389-B54B-049A3B07377CQ37427294-81D90BE6-624F-438B-91BB-D14D1D71C34EQ37595914-A49614C0-4E9B-45C2-A9D8-6D1CA2942C8DQ37639310-D7506D0E-A9D8-44ED-8F46-FDD628DCBBDDQ37870930-0D442979-9858-4727-B045-06EE9074AA4BQ37900151-EB154CD4-A930-492A-B8CE-C09362E3A201Q37900690-EBE7804A-0343-4F1C-BB8F-8FC1167000DCQ37948831-C3ED9AA0-770E-4D93-9BFF-405A9DABCBCCQ37956408-3E533A6D-8F5A-42E1-A3B6-BCBA8D041D8AQ37965612-789CFC6F-F208-49B6-9496-0165D6C78C56Q37970749-C9143B59-FB77-4282-B060-8671593F6445Q37974712-1877468C-CD0D-43DB-925C-7B9A4AC7DFACQ38004088-B4FAD33F-70E5-4B6D-80B5-425780B207B3Q38017726-CD0012B3-F8AE-4553-8935-BD8B6DA0E308Q38036773-C7A67A35-D447-4DFC-8942-1A78DC548BEFQ38064386-DF5072F1-1154-4B3F-AF57-0E35AE198ECEQ38065321-BB59F2BA-B095-4755-A024-AC089895D641Q38072259-79DEE3E5-5D9F-46B9-8042-276B07F0799BQ38087696-F22FEAB9-5F40-441D-9C5C-C805FDE749DFQ38113092-608279EC-64E3-48AF-A1C5-C99067EF327EQ38179267-0324CDAC-09FB-4699-A71E-8B5E1ECB1EABQ38215010-7158968F-614D-4947-8965-DAE883C5B48DQ38857056-2D39A4A4-FF43-4D26-AD64-D55274D36BD8Q38910367-9FD1D8E3-57D6-491F-8DF8-471A7C8C600B
P2860
A meta-analysis of placebo-controlled clinical trials assessing the efficacy and safety of incretin-based medications in patients with type 2 diabetes.
description
article científic
@ca
article scientifique
@fr
articolo scientifico
@it
artigo científico
@pt
bilimsel makale
@tr
scientific article published on 12 July 2010
@en
vedecký článok
@sk
vetenskaplig artikel
@sv
videnskabelig artikel
@da
vědecký článek
@cs
name
A meta-analysis of placebo-con ...... patients with type 2 diabetes.
@en
A meta-analysis of placebo-con ...... patients with type 2 diabetes.
@nl
type
label
A meta-analysis of placebo-con ...... patients with type 2 diabetes.
@en
A meta-analysis of placebo-con ...... patients with type 2 diabetes.
@nl
prefLabel
A meta-analysis of placebo-con ...... patients with type 2 diabetes.
@en
A meta-analysis of placebo-con ...... patients with type 2 diabetes.
@nl
P2093
P921
P356
P1433
P1476
A meta-analysis of placebo-con ...... patients with type 2 diabetes.
@en
P2093
Corinne Lereun
Donna Wright
Walid K H Fakhoury
P356
10.1159/000314690
P577
2010-07-12T00:00:00Z